



**BlueCross  
BlueShield**

Federal Employee Program.

Blue Cross Blue Shield Association  
750 9th St NW, Suite 900  
Washington, D.C. 20001  
1-800-624-5060  
Fax 1-877-378-4727

5.30.005

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2025
<b>Subsection:</b>	Endocrine and Metabolic Drugs	<b>Original Policy Date:</b>	September 8, 2011
<b>Subject:</b>	Egrifra SV	<b>Page:</b>	1 of 4

---

**Last Review Date:** June 12, 2025

---

## Egrifra SV

### Description

#### Egrifra SV (tesamorelin)

---

#### Background

Egrifra SV is approved by the FDA for HIV-associated lipodystrophy which is defined as a condition in which excess fat develops in different areas of the body, especially around the liver, stomach and other abdominal organs commonly observed in HIV-infected patients. Egrifra SV is a growth hormone releasing factor (GRF) analog that acts on pituitary cells in the brain to stimulate the production and release of endogenous growth hormone (1).

Egrifra SV stimulates growth hormone production and increases serum IGF-1. Given that IGF-1 is a growth factor and the effect of prolonged elevations in IGF-1 levels on the development or progression of malignancies is unknown, any pre-existing malignancy should be inactive, and treatment should be completed prior to initiating therapy with Egrifra SV. IGF-1 levels should be monitored closely during Egrifra SV therapy. Careful consideration should be given to discontinuing Egrifra SV in patients with persistent elevations of IGF-1 levels, particularly if the efficacy response is not robust (1).

#### Regulatory Status

FDA-approved indication:

Egrifra SV is a growth hormone releasing factor (GRF) analog indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy (1).

Limitations of Use: (1)

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2025
<b>Subsection:</b>	Endocrine and Metabolic Drugs	<b>Original Policy Date:</b>	September 8, 2011
<b>Subject:</b>	Egrifta SV	<b>Page:</b>	2 of 4

---

- Long-term cardiovascular benefit and safety of Egrifta SV have not been established
- Not indicated for weight loss management (weight neutral effect)
- There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking Egrifta SV

Egrifta SV is contraindicated in women who are pregnant, in patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma, in patients with known hypersensitivity to Egrifta SV and or mannitol, and in patients with active malignancies. Egrifta SV therapy should be discontinued if pregnancy occurs; therefore, a positive pregnancy test prohibits therapy (1).

Preexisting malignancy should be inactive, and its treatment complete prior to starting Egrifta SV therapy (1).

Egrifta SV treatment may result in glucose intolerance. An increased risk of developing diabetes with Egrifta SV relative to placebo was observed. Therefore, glucose status should be carefully evaluated prior to initiating Egrifta SV treatment. Patients must have their glucose status checked routinely (1).

---

## Related policies

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Egrifta SV may be considered **medically necessary** if the conditions indicated below are met.

Egrifta SV may be considered **investigational** for all other indications.

## Prior-Approval Requirements

**Age** 18 years old or older

### Diagnosis

Patient must have the following:

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2025
<b>Subsection:</b>	Endocrine and Metabolic Drugs	<b>Original Policy Date:</b>	September 8, 2011
<b>Subject:</b>	Egrifta SV	<b>Page:</b>	3 of 4

---

HIV-associated lipodystrophy with excess abdominal (visceral) fat

**AND ALL** of the following:

1. Concomitant antiretroviral therapy
2. No evidence of active malignancy
3. Women of child-bearing age must have a negative pregnancy test

---

### **Prior – Approval *Renewal* Requirements**

**Age** 18 years old or older

#### **Diagnosis**

Patient must have the following:

HIV-associated lipodystrophy

**AND ALL** of the following:

1. Concomitant antiretroviral therapy
2. No evidence of active malignancy
3. Physician confirmation of glucose monitoring
4. Visceral adipose tissue (VAT) decrease as shown by a decrease in waist circumference or CT scan
5. Women of child-bearing age must have a negative pregnancy test

#### **Policy Guidelines**

#### **Pre - PA Allowance**

None

#### **Prior - Approval Limits**

**Duration** 3 months

---

#### **Prior – Approval *Renewal* Limits**

**Duration** 6 months

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2025
<b>Subsection:</b>	Endocrine and Metabolic Drugs	<b>Original Policy Date:</b>	September 8, 2011
<b>Subject:</b>	Egrifta SV	<b>Page:</b>	4 of 4

---

## Rationale

### Summary

Egrifta SV is approved for HIV-associated lipodystrophy in patients 18 years of age and older. It is contraindicated in women who are pregnant and preexisting malignancies. Treatment may result in glucose intolerance (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Egrifta SV while maintaining optimal therapeutic outcomes.

### References

1. Egrifta SV [package insert]. Montreal, Canada: Theratechnologies Inc.; February 2022.

## Policy History

Date	Action
December 2012	Annual editorial review and update
June 2014	Annual editorial review and update.
September 2015	Annual editorial review and reference update
September 2016	Annual editorial review and reference update Policy number change from 5.08.05 to 5.30.05
December 2017	Annual editorial review Addition of age requirement in renewal section
November 2018	Annual review and reference update
December 2019	Annual review and reference update
December 2020	Annual review and reference update
March 2021	Annual editorial review. Renamed policy Egrifta SV
March 2022	Annual review
March 2023	Annual review. Changed policy number to 5.30.005
June 2023	Annual review
March 2024	Annual review
June 2024	Annual review
March 2025	Annual editorial review and reference update
June 2025	Annual review

## Keywords

---

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 12, 2025 and is effective on July 1, 2025.**